Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared an article on X:
“If you’re interested in the topic, don’t miss our full review on the current role of anthracyclines in early breast cancer treatment.
We analyze efficacy, toxicity & pt selection, including data recently presented on the predictive value of Oncotype & Mamma Print.”
“Honored to share our article in the NEJM Breast Cancer Update, discussing two perspectives on anthracycline use in breast cancer—a long-debated topic that remains highly relevant today Grateful to co-author this work with Prof. Martine Piccart.”
Redefining the role of anthracyclines in early breast cancer treatment.
Authors: Guilherme Nader-Marta, et al.
